Cellular research / Compound guide

SS-31 guide

SS-31, or elamipretide, is a cardiolipin-binding peptide studied in mitochondrial disease, including Barth syndrome.[1] It has FDA accelerated approval to improve muscle strength in patients with Barth syndrome who weigh at least 30 kg; continued approval may depend on a confirmatory trial.

Editorial still life for cellular research research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

Regulatory status
Elamipretide has FDA accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg; continued approval may depend on a confirmatory trial.[1]
Half-life
3.16 hours (mean after one 40 mg subcutaneous dose in 32 healthy volunteers; 1.48 hours in 7 patients with Barth syndrome), per the FDA integrated review; the label states no half-life.[2]
Route
Subcutaneous, per the label.[1]
Category
Cellular research
Vial size
280 mg

The half-life comes from an FDA review, not the label itself; the label's presentation is a ready-to-use solution of 280 mg in 3.5 mL.[2][1]

What the research says

The elamipretide label describes subcutaneous pharmacokinetics, including approximately 92% bioavailability and peak concentrations within 0.5 to one hour. Investigators also examined renal function because the peptide and its metabolites are excreted in urine. Exposure increased as renal clearance declined in the studied groups.[1]

The FDA review supplies the half-life evidence separately: a study in 32 healthy volunteers reported 3.16 hours after subcutaneous administration, while a smaller repeated-exposure study reported 2.8 hours. PinPoint uses the former value. The same review table reports 1.48 hours in 7 patients with Barth syndrome after the same subcutaneous amount; the populations and designs differ and are not averaged together.[2]

The label's controlled study in twelve participants with Barth syndrome measured walking distance and fatigue as primary endpoints; superiority over placebo was not demonstrated on those endpoints. Muscle-strength observations came from a longer extension. This specific evidence context does not establish broader claims about mitochondrial or athletic performance.[1]

Cited amounts

The label lists elamipretide solution as 280 mg in 3.5 mL, or 80 mg/mL, in single-patient-use vials. The FDA review also reports a 40 mg subcutaneous study in 32 healthy volunteers; a study amount is not a general administration instruction.[1][2]

Open the calculator for amount conversions

Half-life and timing

3.16 hours (mean after one 40 mg subcutaneous dose in 32 healthy volunteers; 1.48 hours in 7 patients with Barth syndrome), per the FDA integrated review; the label states no half-life.[2]

The 3.16-hour input yields 6.32 hours for two halvings and 15.8 hours for five. The final model fraction is 3.125%. This arithmetic uses the single-amount healthy-volunteer context recorded by the library. Its separate steady-state reference is 2.8 hours, which would produce a 14-hour fifth endpoint if used instead. Different research settings therefore produce different model scales. The guide does not treat either as a personal clearance deadline or silently combine the two datasets into one measured curve.[2]

SS-31: modeled fraction over five half-livesStarting at 100 percent, the model halves each 3.16 hours. After 15.8 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%3.16 h50%6.32 h25%9.48 h12.5%12.64 h6.25%15.8 h3.125% Continue to the calculator

Reconstitution

The prepared solution on the label holds 280 mg in its supplied 3.5 mL, which equals 80 mg/mL. No additional liquid is assumed. This concentration check preserves the approved presentation and does not select a dose, syringe volume, or broader indication.[1]

280 mg ÷ 3.5 mL = 80 mg/mL
Open SS-31 conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Track vials and prefilled pens side by side.[3]

The Home curve models your levels between doses from an estimate built on the half-life value stored for each compound, published where a published value exists and an estimate where none does. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

What does an SS-31 peptide dosage search need to distinguish?
The FDA review reports a research amount in healthy volunteers, while the label describes a prepared solution for a specific rare-disease indication. These sources do not establish a general longevity plan.[2][1]
Where does the SS-31 3.16-hour figure come from?
The 3.16-hour figure is the mean half-life after one 40 mg subcutaneous dose in 32 healthy volunteers, from Table 6 of the FDA integrated review. The same table reports 1.48 hours in 7 patients with Barth syndrome. The label does not state a half-life.[2][1]
Why distinguish the SS-31 study amount from the labeled solution?
The healthy-volunteer study reports an amount administered under its research design. The label separately describes the contents and concentration of a prepared solution. A package total does not select an administration amount.[2][1]

Sources

Sources checked against the cited documents on 19 November 2026.

  1. Elamipretide injection, prescribing information (DailyMed)Read 19 November 2026: 1 Indications (accelerated approval), 3, 11, 12.3, 14, 16.Retrieved 2026-11-19 · label
  2. FDA integrated review, NDA 215244 (elamipretide)Read 19 November 2026: Table 6 (single 40 mg SC: 3.16 h in 32 healthy volunteers, 1.48 h in 7 Barth syndrome patients) and Table 7 (2.8 h at steady state, n=5).Retrieved 2026-11-19 · regulator
  3. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description